ArticleActa pharmaceutica Sinica. B2022
miR-7/TGF-
Open access · diamondAbstract read
In one paragraph
Article in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- Lactate-induced miR-7-5p/TRIM33 reprograms metabolic flux to suppress tumor growth and viral reactivation.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- A lactylation-associated gene signature predicts prognosis in neuroblastoma and identifies RPS6KA6 as a candidate biomarker.BMC cancer · 2026Article
- Acidic microenvironment-induced LAMC2 expression promotes proliferation, migration, and pathway regulation in non-small cell lung cancer cells.Frontiers in oncology · 2026Article
- From Mechanism to Clinic: Engineered Bacteria-Nanomaterial Hybrid Systems for Cancer Immunotherapy.Research (Washington, D.C.) · 2026Article
- Comprehensive analysis of the TGF-β signaling pathway: molecular mechanisms, disease drivers, and frontiers in clinical translation.Frontiers in immunology · 2026Review
- Integrated molecular subtyping and functional analysis of circ_0001946/miR-7-5p axis reveals a glucose metabolism-linked regulatory mechanism in ovarian cancer.World journal of surgical oncology · 2025Article
- Low pH, High Stakes: A Narrative Review Exploring the Acid-Sensing GPR65 Pathway as a Novel Approach in Renal Cell Carcinoma.Cancers · 2025Review
- Decoding the tumor immune microenvironment in lung squamous cell carcinoma: characteristics, regulatory mechanisms, and future directions in immunotherapy.Translational lung cancer research · 2025Review
- Brevilin A, a novel LRRC15 inhibitor, exerts potent anti-rheumatoid arthritis effects by inhibiting the LRRC15/STAT3 signaling pathway.Arthritis research & therapy · 2025Article
- Animal models of lung cancer: Phenotypic comparison of different animal models of lung cancer and their application in the study of mechanisms.Animal models and experimental medicine · 2025Review
- Therapeutic targeting of TGF-β in lung cancer.The FEBS journal · 2025Review
- Unraveling the alterations and biomarkers in the tumor microenvironment in lung adenocarcinoma metastases and their indications for therapeutic response and prognosis.Therapeutic advances in medical oncology · 2025Review
- A Robust NSCLC Biomarker- miR-7-5p: ItsMicroRNA (Shariqah, United Arab Emirates) · 2025Article
- Article
- The role of mir-7-5p in cancer: function, prognosis, diagnosis, and therapeutic implications.Molecular biology reports · 2024Review
- Recent advances to address challenges in extracellular vesicle-based applications for lung cancer.Acta pharmaceutica Sinica. B · 2024Review
- In vitro comparative study of multimodal imaging nano-assembled microspheres with two clinical drug-eluting beads loaded with doxorubicin.Drug delivery · 2023Article
- Acidosis promotes the metastatic colonization of lung cancer via remodeling of the extracellular matrix and vasculogenic mimicry.International journal of oncology · 2023Article
- Review
- Prognostic and immune implications of a novel 7-methylguanosine-related microRNA signature in breast invasive carcinoma: from exploration to validation.Journal of cancer research and clinical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 4 countries.
Tao SuJoint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Suchao HuangJoint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Yanmin ZhangJoint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Yajuan GuoJoint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Shuwei ZhangJoint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Jiaji GuanJoint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Mingjing MengJoint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Linxin LiuJoint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Caiyan WangJoint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Dihua YuDepartment of Molecular and Cellular Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hiu-Yee KwanSchool of Chinese Medicine, Hong Kong Baptist University, Hong Kong 999077, China.
Zhiying HuangJoint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Qiuju HuangJoint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Elaine Lai-Han LeungState Key Laboratory of Quality Research in Chinese Medicine/Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau (SAR) 999078, China.
Ming HuDepartment of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, TX 77204, USA.
Ying WangJoint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Zhongqiu LiuJoint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Linlin LuJoint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Guangzhou University of Chinese Medicine · CNMinistry of Education of the People's Republic of China · CNMacau University of Science and Technology · MOHong Kong Baptist University · HKThe University of Texas MD Anderson Cancer Center · USUniversity of Houston · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acidosis, regardless of hypoxia involvement, is recognized as a chronic and harsh tumor microenvironment (TME) that educates malignant cells to thrive and metastasize. Although overwhelming evidence supports an acidic environment as a driver or ubiquitous hallmark of cancer progression, the unrevealed core mechanisms underlying the direct effect of acidification on tumorigenesis have hindered the discovery of novel therapeutic targets and clinical therapy. Here, chemical-induced and transgenic mouse models for colon, liver and lung cancer were established, respectively. miR-7 and TGF-
Indexed as
Acidic tumor microenvironmentAOM/DSS, azoxymethane/dextran sodium sulfateB[a]P, benzopyreneCA9, carbonic anhydrase IXDAB, diaminobenzidineDAVID, Database for Annotation, Visualization, and Integrated DiscoveryDEGs, differentially expressed genesDEN, diethylnitrosamineDEPs, differentially expressed proteinsDSS, dextran sodium sulfateGEMMs, genetically engineered tumor mouse modelsGSEA, gene set enrichment analysisIHC, immunohistochemistryInvasionISH, in situ hybridizationKEGG, Kyoto Encyclopedia of Genes and GenomesLUAD, lung adenocarcinomaLung cancerLUSC, lung squamous cell carcinomaMCT, monocarboxylate transporterMetastasismiR-7-5pNHE, Na+/H+ exchangerNSCLC, non-small cell lung cancerPCR, polymerase chain reactionpHTGF-β2TME, tumor microenvironmentTMT, tandem mass taggingV-ATPase, vacuolar ATPase
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.